JP2021522246A5 - - Google Patents
Info
- Publication number
- JP2021522246A5 JP2021522246A5 JP2020559437A JP2020559437A JP2021522246A5 JP 2021522246 A5 JP2021522246 A5 JP 2021522246A5 JP 2020559437 A JP2020559437 A JP 2020559437A JP 2020559437 A JP2020559437 A JP 2020559437A JP 2021522246 A5 JP2021522246 A5 JP 2021522246A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- cancer
- azd5991
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664356P | 2018-04-30 | 2018-04-30 | |
| US62/664,356 | 2018-04-30 | ||
| PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522246A JP2021522246A (ja) | 2021-08-30 |
| JP2021522246A5 true JP2021522246A5 (enExample) | 2022-05-06 |
Family
ID=66794041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559437A Withdrawn JP2021522246A (ja) | 2018-04-30 | 2019-04-29 | 癌治療のための併用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210030718A1 (enExample) |
| EP (1) | EP3787620A1 (enExample) |
| JP (1) | JP2021522246A (enExample) |
| KR (1) | KR20210005182A (enExample) |
| CN (1) | CN112040944A (enExample) |
| AU (1) | AU2019263026B2 (enExample) |
| BR (1) | BR112020022020A2 (enExample) |
| CA (1) | CA3097486A1 (enExample) |
| EA (1) | EA202092540A1 (enExample) |
| MA (1) | MA52499A (enExample) |
| MX (1) | MX2020011453A (enExample) |
| SG (1) | SG11202010528XA (enExample) |
| TW (1) | TW202014184A (enExample) |
| WO (1) | WO2019211721A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4054582B1 (en) * | 2019-11-04 | 2025-09-03 | Astrazeneca AB | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
| JP2023510135A (ja) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | 大環状化合物 |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689878B1 (en) | 2011-07-19 | 2021-10-06 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| AU2015300966A1 (en) * | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| ES2791319T3 (es) | 2016-04-22 | 2020-11-03 | Astrazeneca Ab | Inhibidores de MCL1 macrocíclicos para tratar el cáncer |
| CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/zh unknown
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/es unknown
- 2019-04-29 MA MA052499A patent/MA52499A/fr unknown
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/pt not_active IP Right Cessation
- 2019-04-29 EA EA202092540A patent/EA202092540A1/ru unknown
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/zh active Pending
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/ja not_active Withdrawn
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en not_active Ceased
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021522246A5 (enExample) | ||
| JP2023541430A5 (enExample) | ||
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2023541432A5 (enExample) | ||
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| JP2024516795A5 (enExample) | ||
| JP2024516363A5 (enExample) | ||
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| AU2018360559A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| Mornex et al. | Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art | |
| JP2021511352A5 (enExample) | ||
| JP2023537290A5 (enExample) | ||
| CN101175495A (zh) | 联合疗法 | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| TW202023568A (zh) | 用於治療癌症之組合療法 | |
| Kramer | Radiation therapy and chemotherapy combination | |
| JP2022509257A5 (enExample) | ||
| CN102105147B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| JP7315167B2 (ja) | 抗がん剤投与により生じる皮膚障害の治療又は予防剤 | |
| WO2008135792A1 (en) | Pm00104 compound for use in cancer therapy | |
| HK40040830A (en) | Combination therapy for treating cancer | |
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| TW201012467A (en) | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |